Welcome to our dedicated page for Zomedica news (Ticker: ZOMDF), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zomedica's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zomedica's position in the market.
Zomedica (OTCQB:ZOMDF) has expanded its TRUFORMA diagnostic platform by adding feline testing capability to its cobalamin & folate assay, previously only available for canine patients. The multiplexed assay, which combines two critical tests in one, delivers results in under 25 minutes at the point of care.
Originally launched for dogs in early 2024, this first-of-its-kind in-clinic test now addresses the critical need for rapid diagnosis in feline patients with gastrointestinal conditions. According to veterinary experts, this expansion is particularly significant as feline patients with GI disease often deteriorate more rapidly than canine patients, making quick results crucial for timely treatment.
Zomedica (OTCQB:ZOMDF) has strengthened its intellectual property portfolio with four new U.S. patents for its TRUVIEW and TRUFORMA diagnostic platforms. Three patents relate to the TRUVIEW Microscope's automated slide processing systems, while the fourth patent protects acoustic wave sensor technology with crowding agents.
The company now holds 83 U.S. patents and 145 international patents, along with 37 U.S. and 116 foreign trademarks. These innovations position Zomedica to compete in the veterinary diagnostics market, currently valued at $8-11 billion and projected to reach $17-22 billion by 2030-2032, growing at a 9-11% CAGR.
Zomedica (OTCQB:ZOMDF) announces its upcoming Fourth Friday at Four webinar on September 26, 2025 at 4:00 PM ET, featuring their TRUVIEW digital cytology microscope. The webinar will showcase how TRUVIEW is revolutionizing veterinary diagnostics by enabling the creation of automated laboratory-quality blood films from fresh blood samples.
The TRUVIEW system addresses historical challenges in veterinary practices by eliminating technical barriers to blood film preparation, allowing clinics to return to gold-standard protocols. The technology uniquely enables blood film analysis before cell bloat occurs from EDTA preservatives, marking a significant advancement in point-of-care diagnostics.
Zomedica (OTCQB:ZOMDF) has expanded its distribution agreement with UXR Inc. to strengthen its presence in the Canadian veterinary market. Under the agreement, UXR becomes the exclusive distributor of Zomedica's PulseVet® system and VETGuardian® products in Canada, along with distribution rights for the Assisi® product portfolio.
The expansion targets a market of over 4,000 veterinary practices in Canada, with a projected 7% compound annual growth rate. The partnership aims to enhance access to Zomedica's innovative therapeutic and monitoring solutions for the country's 28 million pets, focusing on technologies that reduce pain, improve recovery, and enhance monitoring in veterinary practices.
Zomedica (OTCQB:ZOMDF) has announced a strategic distribution partnership with Pioneer Veterinary Products Limited to strengthen its presence in the UK veterinary market. The agreement initially focuses on distributing Zomedica's TRUFORMA® diagnostic platform across England, Scotland, Wales, and Northern Ireland, with plans to later introduce VETGuardian® remote monitoring technology.
Pioneer will serve as an exclusive distributor for the small animal market and a non-exclusive distributor for equine products. The TRUFORMA platform provides reference lab-quality results for diagnosing endocrine and thyroid conditions in dogs, cats, and horses, while VETGuardian offers wireless, contactless monitoring of animal vitals in surgical and post-operative care settings.
Zomedica (OTCQB:ZOMDF) has announced a strategic two-year partnership with VerticalVet, a major veterinary Group Purchasing Organization serving over 2,600 independent practices across the United States. Through this collaboration, VerticalVet members will receive preferred access to Zomedica's advanced veterinary technologies.
The partnership includes access to several key technologies: the PulseVet® shock wave therapy system for healing and pain management, VETGuardian® remote monitoring platform, Assisi® targeted pulsed electromagnetic field therapy devices, and Vetigel® hemostatic gel for surgical bleeding control.
Zomedica (OTCQB:ZOMDF) announced its upcoming Fourth Friday at Four webinar on August 22, 2025, focusing on their VETIGEL® hemostatic gel product. The webinar, scheduled for 4:00 PM ET, will showcase this plant-based solution designed for rapid bleeding control in veterinary medicine.
VETIGEL® offers veterinary professionals a quick and efficient method for managing soft tissue and superficial wounds through its syringe-based delivery system. The product accelerates clot formation and seals wounds, eliminating the need for traditional methods like manual pressure or cautery. The webinar will feature clinical case studies, real-world outcomes, and testimonials from veterinary professionals, followed by a live Q&A session with Zomedica's product and commercial leaders.
Zomedica (OTCQB:ZOMDF), a veterinary health company, reported strong Q2 2025 financial results with revenue growing 14% to $7.0 million, marking its 18th consecutive quarter of year-over-year growth. The company achieved 67% gross margins and maintained a robust liquidity position of $59.1 million.
Key highlights include 86% growth in the Diagnostics segment, primarily driven by TRUFORMA platform adoption, and 21% growth in Consumable sales to $5.3 million. The Therapeutic Device segment, comprising PulseVet and Assisi products, grew 8% to $6.2 million. International sales increased by 13% year-over-year. Operating expenses decreased by $0.7 million, though the company reported a net loss of $7.4 million.
Zomedica (OTCQB:ZOMDF) announces its upcoming Fourth Friday at Four webinar on July 25, 2025, focusing on their Assisi product line of targeted Pulsed Electromagnetic Field (tPEMF) therapy devices. The webinar will showcase their drug-free solutions including the Assisi Loop®, Assisi Loop Lounge®, and Calmer Canine® products.
The session will feature insights into tPEMF technology, clinical outcomes, and real-world applications in veterinary care. Led by Nicole Westfall, Senior VP of Marketing, and Mialisa Gluckert, Senior Director of Assisi Commercialization, the webinar will demonstrate how these non-invasive treatments are revolutionizing pain and inflammation management in companion animals.
Zomedica (OTCQB:ZOMDF) has announced a strategic sponsorship agreement between its PulseVet shock wave device and the World Equestrian Center - Ocala (WEC), establishing PulseVet as the official shock wave therapy provider at the venue. The partnership includes comprehensive brand visibility through arena signage, digital promotions, and features in WEC publications.
The collaboration aims to enhance veterinary care for elite equine athletes by providing non-invasive shock wave therapy for musculoskeletal injuries. The agreement includes on-site educational resources, promotional materials, and hospitality privileges during WEC events, including discounted lodging and VIP access.
FAQ
What is the current stock price of Zomedica (ZOMDF)?
What is the market cap of Zomedica (ZOMDF)?
